Fermentalg: TP ICAP Midcap confirms purchase

(CercleFinance.com) - On Wednesday, TP ICAP Midcap renewed its buy recommendation and 0.
6 euro price target for Fermentalg shares, following a visit to a site in Libourne.

In a note entitled "On the road to profitability", the brokerage firm highlights the company's strengthened position in the algal omega-3 market, thanks to a diversification strategy deemed "ambitious" and controlled industrialization.

In its view, outsourcing production to the Huvepharma laboratory will limit capital expenditure and optimize working capital, while supporting growth.

The investment bank also believes that the company has the means to reach operating breakeven by the end of 2026, a key factor in its stock market revaluation, thanks to the ramp-up of its three existing markets (dietary supplements, animal feed and infant formula).

TP ICAP Midcap also highlights strong growth in demand, as well as possible expansion into new markets (aquaculture, cosmetics, functional foods).

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.